Molecular epidemiology of lung cancer

肺癌的分子流行病学

• 批准号: 7473983
• 负责人: Anil Vachani
• 金额: $ 13.84万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-09 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7473983
• 关键词: Accounting; Adjuvant; Adjuvant Therapy; Age; Award; Biological; Biometry; Cancer Patient; Candidate Disease Gene; Characteristics; Chest; Classification; Clinical; Cohort Studies; Complex; Critical Care; Cross-Sectional Studies; Curative Surgery; Development; Disease; Disease regression; Doctor of Medicine; Epidemiologic Studies; Epidemiology; Excision; Faculty; Foundations; Gender; Genes; Genetic; Genetic Polymorphism; Genetic Variation; Genotype; Goals; Haplotypes; Hypersensitivity; Immune; Immune Tolerance; Immune system; Immunosuppressive Agents; Immunotherapeutic agent; Incidence; Individual; Instruction; Laboratories; Lead; Lung; Malignant Neoplasms; Malignant neoplasm of lung; Molecular; Molecular Epidemiology; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Numbers; Operative Surgical Procedures; Outcome; Patients; Pattern; Pennsylvania; Play; Preceptorship; Recurrence; Relative (related person); Research; Research Personnel; Research Proposals; Resected; Risk; Risk Factors; Role; Staging; Survival Rate; Techniques; Testing; Time; Training; Trees; Universities; career; cell type; design; gene interaction; genetic association; insight; lymph nodes; medical schools; member; mortality; novel; programs; size; trait; tumor; tumor progression

DESCRIPTION (provided by applicant): Anil Vachani, M.D. is a member of the Pulmonary, Allergy, and Critical Care Division at the University of Pennsylvania School of Medicine and is a faculty-fellow in the Department of Biostatistics and Epidemiology. The career development component of the award proposed herein includes a preceptorship with Dr. Timothy Rebbeck, Director of Cancer Epidemology at Penn, and advanced coursework in molecular epidemiology. Additional training will be obtained in laboratory techniques necessary for the conduct of well designed molecular epidemiologic studies. This program of didactic and applied instruction will extend Dr. Vachani's training, will be directly applicable to timely completion of his research proposal, and will provide him with the necessary foundation to become an independent investigator in the molecular epidemiology of lung cancer. The goal of the proposed research is to evaluate the role of candidate genetic polymorphisms in the determination of outcomes among patients with lung cancer. Lung cancer is the most common worldwide cause of major cancer incidence and mortality. At present, the ability to predict outcome in patients with surgically resected tumors is limited. Although surgical therapy may be curative, a number of variables including mechanisms related to the immune system may influence the risk of recurrence and survival in patients with resected lung cancer. The hypothesis underlying Dr. Vachani's project is that higher levels of immune tolerance and escape play a key role in the outcome of NSCLC. More specifically, we will test the association of genetic variation in immunosuppressive genes with tumor characteristics and outcomes in patients with NSCLC. Gene-gene interactions and higher order interactions will also be evaluated. Results from this project may provide valuable insight into immune mechanisms involved in lung cancer progression and allow for the identification of patients that may benefit from adjuvant therapy, particularly novel immunotherapeutic strategies.

描述（由申请人提供）：Anil Vachani，医学博士是宾夕法尼亚大学医学院肺部、过敏和重症监护部的成员，也是生物统计学和流行病学系的研究员。本文提出的奖项的职业发展部分包括与宾夕法尼亚大学癌症流行病学主任Timothy Rebbeck博士的指导，以及分子流行病学的高级课程。将获得进行精心设计的分子流行病学研究所需的实验室技术方面的额外培训。这一教学和应用指导计划将延长Vachani博士的培训，将直接适用于及时完成他的研究计划，并将为他成为肺癌分子流行病学的独立研究者提供必要的基础。这项研究的目的是评估候选基因多态性在决定肺癌患者预后中的作用。肺癌是世界范围内最常见的主要癌症发病率和死亡率的原因。目前，预测手术切除肿瘤患者预后的能力有限。虽然手术治疗可能是治愈性的，但包括免疫系统相关机制在内的许多变量可能会影响切除肺癌患者的复发风险和生存率。Vachani博士项目的假设是，较高水平的免疫耐受和逃避在NSCLC的结局中起着关键作用。更具体地说，我们将测试免疫抑制基因的遗传变异与NSCLC患者的肿瘤特征和预后的相关性。还将评价基因-基因相互作用和更高阶相互作用。该项目的结果可能为肺癌进展中涉及的免疫机制提供有价值的见解，并允许识别可能受益于辅助治疗的患者，特别是新的免疫策略。